Operating

Change in Accrued Liabilities

Bristol-Myers Squibb Change in Accrued Liabilities increased by 93.3% to $1.70B in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 6.4%, from $1.82B to $1.70B.

Analysis

StatementCash Flow Statement
SectionOperating
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ1 2007
Last reportedQ3 2025

How to read this metric

An increase represents a source of cash through deferred payment, while a decrease represents a cash outflow as obligations are settled.

Detailed definition

Reflects the change in obligations for expenses incurred but not yet invoiced or paid, such as employee compensation, ta...

Peer comparison

Standard operating cash flow component found in almost all corporate financial statements.

Metric ID: cf_change_in_accrued_liabilities

Historical Data

15 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q1 '23Q2 '23Q3 '23Q1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25
Value$215.00M$908.00M$0.00-$930.00M$520.00M$1.14B-$910.00M$492.00M$1.53B-$665.00M$735.00M$1.82B-$627.00M$881.00M$1.70B
QoQ Change+322.3%-100.0%+155.9%+119.2%-179.8%+154.1%+211.6%-143.4%+210.5%+147.5%-134.5%+240.5%+93.3%
YoY Change+141.9%+25.6%+2.2%-5.4%+34.5%+26.9%+49.4%+18.7%+5.7%+19.9%-6.4%
Range-$930.00M$1.82B
CAGR+80.6%
Avg YoY Growth+28.4%
Median YoY Growth+19.9%
Current Streak2 quarters growth

Frequently Asked Questions

What is Bristol-Myers Squibb's change in accrued liabilities?
Bristol-Myers Squibb (BMY) reported change in accrued liabilities of $1.70B in Q3 2025.
How has Bristol-Myers Squibb's change in accrued liabilities changed year-over-year?
Bristol-Myers Squibb's change in accrued liabilities decreased by 6.4% year-over-year, from $1.82B to $1.70B.
What does change in accrued liabilities mean?
The net change in expenses that have been recognized but not yet paid.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.